|
|
7068 Koll Center Parkway, Suite 401
Pleasanton, CA 94566-3111 USA
phone:(925) 249-4000
fax:925-249-4040
|
|
| Symbol |
LIPD |
| Exchange |
NASDAQ |
| Founded |
0 |
| Employees |
15 |
|
|
| www.lipidsciences.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Treat medical conditions in which lipids or fat components play a key role. |
|
| Management |
| S. Lewis Meyer, Ph.D., President, CEO; Sandra Gardiner, Chief Financial Officer; Jo-Ann Maltais, Ph.D, VP Scientific Affairs; Dale L. Richardson, VP Business Development;
|
| |
|
|
|
|
|
|
|
| Keywords |
| cardiovascular disease, hiv, lipid, cholesterol, hdl, HIVAIDS |
|
|
|
| Description |
|
Lipid Sciences, Inc. is a development-stage biotechnology company engaged in research and development of products and processes intended to treat major medical indications such as cardiovascular disease, human immunodeficiency virus (HIV) and other viral infections, in which lipids or fat components play a key role. |
|
| Products / Services |
The Company's HDL Therapy is designed to increase or enhance the performance of HDL (high density lipoprotein) or good cholesterol, through the stimulation of a patient's natural Reverse Cholesterol Transport system.
The Company's Viral Immunotherapy platform is focused on the removal of lipid coatings from viruses and other lipid-containing infectious agents by application of the Company's delipidation technology.
|
|
| Technology / Differentiation |
| The Company's technologies are based on a process that selectively and rapidly removes lipids, such as cholesterol from lipoproteins or viruses circulating in blood plasma without disrupting protein function. This process of lipid removal, known as delipidation, potentially improves the condition while enhancing the body's natural ability to heal itself. |
|
| Market / Customers |
Lipid Sciences is focused on applications for delipidation in two main areas: cardiovascular disease, using its HDL Therapy platform, and viral infections, using its Viral Immunotherapy platform.
|
|
| Status |
| Lipid Sciences is developing its Viral Immunotherapy technology to establish an approach for the preparation of vaccines against lipid-enveloped pathogens. The first indication it is pursuing with the Viral Immunotherapy process is the development of an autologous therapeutic vaccine for use against HIV. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
